Dr. Raffi Karagozian, MD

Dr. Karagozian practices at Tufts Medical Center in Boston, Massachusetts, part of Tufts Medicine.

Dr. Karagozian's NPI, 1356394233, was assigned on May 19, 2006. Dr. Karagozian graduated from Boston University School of Medicine in 2001. Dr. Karagozian holds Massachusetts license 219980.

Dr. Karagozian's primary practice is Tufts Medical Center, at 800 Washington Street, Boston, MA 02111 in Suffolk County. The practice phone is (617) 636-5000.

Dr. Karagozian's primary practice is Tufts Medical Center in Boston, Massachusetts, part of Tufts Medicine. Dr. Karagozian is also affiliated with Lowell General Hospital. The medical group on file is Pratt Medical Group, Inc. - General Medical Associates (General Internal Medicine). Dmand AI also links Dr. Karagozian to 1 more hospital and 1 imaging center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Karagozian practices, 4 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Karagozian's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Karagozian is licensed in Massachusetts.

CMS data shows 416 Medicare services from Dr. Karagozian across 10 procedure codes in 2024, for 274 Medicare patients. Medicare paid $29,736 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 274 Medicare patients who saw Dr. Karagozian in 2024. The largest group is 65 to 74, with 146 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 38% are also on Medicaid. Their average risk score is 1.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Karagozian's median patient age at 57, with 53% women.

In 2024, Dr. Karagozian wrote 644 Medicare Part D claims for 176 patients. 81% of them were for generic drugs. CMS names the drug for 544 of them, across 20 drugs with 11 or more claims each, at $424,286 in total drug cost. In 2023, CMS named 399 claims across 15 drugs.

Dr. Karagozian accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Karagozian as offering telehealth. CMS counts 35 procedures of colonoscopy by Dr. Karagozian, more than 56% of the clinicians it reports for that procedure.

Dmand AI links 50 papers to Dr. Karagozian, published from 2013 to 2025. 2021 was the busiest year, with 12. The most frequent topics are Hospitals, Liver Cirrhosis and Postoperative Complications. Dr. Karagozian has published most often in J Clin Gastroenterol. Dr. Karagozian's most frequent co-authors are Gaurav Bhardwaj, MD, Richa Bhardwaj, MD and Hassan Aziz, MD.

Dmand AI links Dr. Karagozian to 1 clinical trial. Conditions studied include Liver Cirrhosis, Biliary and Cholestasis, Intrahepatic.

CMS Open Payments shows 156 general payments to Dr. Karagozian from 24 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 46% of the total. Gilead Sciences, Inc. paid the most, $15,548.

Dr. Karagozian graduated from Boston University School of Medicine in 2001.